Top

Published in:

Open Access 01-12-2005 | Research

Human lung cancer cells express functionally active Toll-like receptor 9

Authors: Daniel Droemann, Dirk Albrecht, Johannes Gerdes, Artur J Ulmer, Detlev Branscheid, Ekkehard Vollmer, Klaus Dalhoff, Peter Zabel, Torsten Goldmann

Published in: Respiratory Research | Issue 1/2005

Abstract

Background

CpG-oligonucleotides (CpG-ODN), which induce signaling through Toll-like receptor 9 (TLR9), are currently under investigation as adjuvants in therapy against infections and cancer. CpG-ODN function as Th-1 adjuvants and are able to activate dendritic cells. In humans TLR9 has been described to be strongly expressed in B-lymphocytes, monocytes, plasmacytoid dendritic cells and at low levels in human respiratory cells. We determined whether a direct interaction of bacterial DNA with the tumor cells themselves is possible and investigated the expression and function of TLR9 in human malignant solid tumors and cell lines. TLR9 expression by malignant tumor cells, would affect treatment approaches using CpG-ODN on the one hand, and, on the other hand, provide additional novel information about the role of tumor cells in tumor-immunology.

Methods

The expression of TLR9 in HOPE-fixed non-small lung cancer, non-malignant tissue and tumor cell lines was assessed using immunohistochemistry, confocal microscopy, in situ hybridization, RT-PCR and DNA-sequencing. Apoptosis and chemokine expression was detected by FACS analysis and the Bio-Plex system.

Results

We found high TLR9 signal intensities in the cytoplasm of tumor cells in the majority of lung cancer specimens as well as in all tested tumor cell lines. In contrast to this non-malignant lung tissues showed only sporadically weak expression. Stimulation of HeLa and A549 cells with CpG-ODN induced secretion of monocyte chemoattractant protein-1 and reduction of spontaneous and tumor necrosis factor-alpha induced apoptosis.

Conclusions

Here we show that TLR9 is expressed in a selection of human lung cancer tissues and various tumor cell lines. The expression of functionally active TLR9 in human malignant tumors might affect treatment approaches using CpG-ODN and shows that malignant cells can be regarded as active players in tumor-immunology.

Belvin MP, Anderson KV: A conserved signaling pathway: the Drosophila toll-dorsal pathway. Annu Rev Cell Dev Biol 1996, 12:393–416.CrossRefPubMed

Beutler B, Rehli M: Evolution of the TIR, tolls and TLRs: functional inferences from computational biology. Curr Top Microbiol Immunol 2002, 270:1–21.PubMed

Medzhitov R, Janeway C Jr: Innate immunity. N Engl J Med 2000,343(5):338–344.CrossRefPubMed

Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A: Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999,285(5428):736–739.CrossRefPubMed

Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001,413(6857):732–738.CrossRefPubMed

Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998,282(5396):2085–2088.CrossRefPubMed

Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001,410(6832):1099–1103.CrossRefPubMed

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo , Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 2000,408(6813):740–745.CrossRefPubMed

Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A: The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998,187(12):2097–2101.CrossRefPubMedPubMedCentral

10.

Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002,32(7):1958–1968.CrossRefPubMed

11.

Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop 1991, (262):3–11.

12.

Shimada S, Yano O, Tokunaga T: In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn J Cancer Res 1986,77(8):808–816.PubMed

13.

Steinman RM, Dhodapkar M: Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001,94(4):459–473.CrossRefPubMed

14.

Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997,3(8):849–854.CrossRefPubMed

15.

Sparwasser T, Vabulas RM, Villmow B, Lipford GB, Wagner H: Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 2000,30(12):3591–3597.CrossRefPubMed

16.

Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G: Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 2002,32(11):3235–3245.CrossRefPubMed

17.

Okamoto M, Sato M: Toll-like receptor signaling in anti-cancer immunity. J Med Invest 2003,50(1–2):9–24.PubMed

18.

Wooldridge JE, Weiner GJ: CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Curr Opin Oncol 2003,15(6):440–445.CrossRefPubMed

19.

Olert J, Wiedorn KH, Goldmann T, Kuhl H, Mehraein Y, Scherthan H, Niketeghad F, Vollmer E, Muller AM, Muller-Navia J: HOPE fixation: a novel fixing method and paraffin-embedding technique for human soft tissues. Pathol Res Pract 2001,197(12):823–826.CrossRefPubMed

20.

Goldmann T, Wiedorn KH, Kuhl H, Olert J, Branscheid D, Pechkovsky D, Zissel G, Galle J, Muller-Quernheim J, Vollmer E: Assessment of transcriptional gene activity in situ by application of HOPE-fixed, paraffin-embedded tissues. Pathol Res Pract 2002,198(2):91–95.CrossRefPubMed

21.

Umland O, Ulmer AJ, Vollmer E, Goldmann T: HOPE fixation of cytospin preparations of human cells for in situ hybridization and immunocytochemistry. J Histochem Cytochem 2003,51(7):977–980.CrossRefPubMed

22.

Droemann D, Goldmann T, Branscheid D, Clark R, Dalhoff K, Zabel P, Vollmer E: Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol 2003,119(2):103–108.PubMed

23.

Roche Molecular Biochemicals: Nonradioactive in situ hybridization application manual. Roche Diagnostics, Boehringer Mannheim, Mannheim, Germany. Ref Type: Generic 2nd edition. 1996.

24.

Goldmann T, Vollmer E, Gerdes J: What's Cooking? Detection of Important Biomarkers in HOPE-Fixed, Paraffin-Embedded Tissues Eliminates the Need for Antigen Retrieval. Am J Pathol 2003,163(6):2638–2640.CrossRefPubMedPubMedCentral

25.

Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S: Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003,33(6):1633–1641.CrossRefPubMed

26.

Gold P, Freedman SO: Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorbtion techniques:. J Exp Med 1965, 121:439–462.CrossRefPubMedPubMedCentral

27.

Grunert F, Luckenbach GA, Haderlie B, Schwarz K, von Kleist S: Comparison of colon-, lung-, and breast-derived carcinoembryonic antigen and cross-reacting antigens by monoclonal antibodies and fingerprint analysis. Ann N Y Acad Sci 1983, 417:75–85.CrossRefPubMed

28.

Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM: Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001,167(7):3555–3558.CrossRefPubMed

29.

Platz J, Beisswenger C, Dalpke A, Koczulla R, Pinkenburg O, Vogelmeier C, Bals R: Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 2004,173(2):1219–1223.CrossRefPubMed

30.

Medzhitov R: CpG DNA: security code for host defense. Nat Immunol 2001,2(1):15–16.CrossRefPubMed

31.

Park Y, Lee SW, Sung YC: Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3'-OH kinase pathway. J Immunol 2002,168(1):5–8.CrossRefPubMed

32.

Yi AK, Hornbeck P, Lafrenz DE, Krieg AM: CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol 1996,157(11):4918–4925.PubMed

33.

Decker T, Schneller F, Kronschnabl M, Dechow T, Lipford GB, Wagner H, Peschel C: Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000,28(5):558–568.CrossRefPubMed

34.

Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, Peschel C: Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000,95(3):999–1006.PubMed

35.

Smith JB, Wickstrom E: Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. J Natl Cancer Inst 1998,90(15):1146–1154.CrossRefPubMed

36.

Carpentier AF, Chen L, Maltonti F, Delattre JY: Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999,59(21):5429–5432.PubMed

37.

Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997,89(8):2994–2998.PubMed

38.

Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T: Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984,72(4):955–962.PubMed

39.

Ballas ZK, Rasmussen WL, Krieg AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996,157(5):1840–1845.PubMed

40.

Nagai M, Masuzawa T: Vaccination with MCP-1 cDNA transfectant on human malignant glioma in nude mice induces migration of monocytes and NK cells to the tumor. Int Immunopharmacol 2001,1(4):657–664.CrossRefPubMed

41.

Nokihara H, Yanagawa H, Nishioka Y, Yano S, Mukaida N, Matsushima K, Sone S: Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice. Cancer Res 2000,60(24):7002–7007.PubMed

Title: Human lung cancer cells express functionally active Toll-like receptor 9
Authors: Daniel Droemann
Dirk Albrecht
Johannes Gerdes
Artur J Ulmer
Detlev Branscheid
Ekkehard Vollmer
Klaus Dalhoff
Peter Zabel
Torsten Goldmann
Publication date: 01-12-2005
Publisher: BioMed Central
Published in: Respiratory Research / Issue 1/2005
Electronic ISSN: 1465-993X
DOI: https://doi.org/10.1186/1465-9921-6-1

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Human lung cancer cells express functionally active Toll-like receptor 9

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2005

Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis

Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients

Variation in conserved non-coding sequences on chromosome 5q and susceptibility to asthma and atopy

Induction of p38- and gC1qR-dependent IL-8 expression in pulmonary fibroblasts by soluble hepatitis C core protein

Pathophysiological classification of chronic rhinosinusitis

Relation of exaggerated cytokine responses of CF airway epithelial cells to PAO1 adherence

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page